Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Short-term Investments (2020 - 2024)

Xeris Biopharma Holdings' Short-term Investments history spans 5 years, with the latest figure at $10.2 million for Q3 2024.

  • For the quarter ending Q3 2024, Short-term Investments fell 48.72% year-over-year to $10.2 million, compared with a TTM value of $10.2 million through Sep 2024, down 48.72%, and an annual FY2023 reading of $5.0 million, changed N/A over the prior year.
  • Short-term Investments for Q3 2024 was $10.2 million at Xeris Biopharma Holdings, down from $20.0 million in the prior quarter.
  • The five-year high for Short-term Investments was $96.2 million in Q4 2020, with the low at $5.0 million in Q4 2023.
  • Average Short-term Investments over 5 years is $29.0 million, with a median of $24.7 million recorded in 2024.
  • Year-over-year, Short-term Investments crashed 72.16% in 2022 and then skyrocketed 112.78% in 2023.
  • Tracing XERS's Short-term Investments over 5 years: stood at $96.2 million in 2020, then plummeted by 63.45% to $35.2 million in 2021, then tumbled by 73.48% to $9.3 million in 2022, then plummeted by 46.35% to $5.0 million in 2023, then soared by 103.32% to $10.2 million in 2024.
  • Per Business Quant, the three most recent readings for XERS's Short-term Investments are $10.2 million (Q3 2024), $20.0 million (Q2 2024), and $24.7 million (Q1 2024).